MeSH D017192 - bacterial skin diseases
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D017192:Â
Bacterial skin diseases
D000197:Cervicofacial actinomycosis
0 Companies
0 Drugs
Success rate
D004473:Ecthyma
0 Companies
0 Drugs
Success rate
D004886:Erysipelas
0 Companies
0 Drugs
Success rate
D004894:Erythrasma
D006100:Granuloma inguinale
D008271:Mycetoma
0 Companies
0 Drugs
Success rate
D010874:Pinta
0 Companies
0 Drugs
Success rate
D012226:Rhinoscleroma
0 Companies
0 Drugs
Success rate
D013207:Staphylococcal skin infections
D013591:Cutaneous syphilis
0 Companies
0 Drugs
Success rate
D014382:Cutaneous tuberculosis
0 Companies
0 Drugs
Success rate
D015001:Yaws
0 Companies
0 Drugs
Success rate
D015787:Erythema chronicum migrans
0 Companies
0 Drugs
Success rate
D016917:Bacillary angiomatosis
0 Companies
0 Drugs
Success rate
D017497:Hidradenitis suppurativa
D058066:Digital dermatitis
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| AbbVie | Dalbavancin | Xydalba |  | 2015-02-19 |  |  |
| Avibactam, Ceftazidime | Avycaz | 2026-01-07 | 2015-02-25 |  |  | |
| Accord Healthcare | Daptomycin | Daptomycin |  | 2019-06-24 |  |  |
| Tigecycline | Tigecycline |  | 2018-01-18 |  |  | |
| Tigecycline | Tigecycline Accord |  | 2020-04-17 |  |  | |
| Alembic Pharmaceuticals | Linezolid | Linezolid |  | 2015-12-21 |  |  |
| Alkem Laboratories | Cephalexin | Cephalexin |  | 2010-12-20 |  |  |
| Linezolid | Linezolid |  | 2015-12-21 |  |  | |
| Allergan | Ofloxacin | Ocuflox |  | 1993-07-30 |  |  |
| Ampicillin | Ampicillin |  | 1988-10-24 |  |  | |
| Levofloxacin | Levofloxacin |  | 2011-02-10 |  |  | |
| Nafcillin | Nafcillin |  | 1988-10-26 |  |  | |
| Altaire Pharmaceuticals | Ofloxacin | Ofloxacin |  | 2013-04-29 |  |  |
1
2
3
4
5
6
...
16
>
Clinical Trials
Historical Success Rate
Phase 1
20%2/10
Phase 2
43%3/7
Phase 3
93%52/56
Approved: 46Overall Success rate: 8%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
5
6
...
11
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use